Nicotine Risk-Benefit Analysis with Low-Dose Patches
Created with Gemini AI by Troy Roach -- 28, Sept 2025 Risk-Benefit Analysis in Long-COVID and other complex diseases -- Hope vs Innaction Each person needs to know the risks and benefits of any intervention. I appreciate the concern for safety — it’s important, especially in a community where people have already endured so much medical neglect. But I think your stance of taking zero risks is missing the other side of the risk/benefit equation. Yes, nicotine is vasoactive (although it increases bloodflow to the brain and other major organs). Yes, we should be cautious with anyone who has underlying cardiovascular disease. But the blanket framing of “this could go bad fast” doesn’t reflect the actual data we now have. We published an N=231 study on nicotine use in Long COVID and ME/CFS . This isn’t just scattered anecdotes anymore. The majority of participants reported sustained improvement in symptoms such as fatigue, brain fog, orthostatic intolerance, and post-exertional malaise. ...